CN113573714A - 用骨化二醇控制甲状旁腺功能亢进进展的方法和其中使用的组合物 - Google Patents

用骨化二醇控制甲状旁腺功能亢进进展的方法和其中使用的组合物 Download PDF

Info

Publication number
CN113573714A
CN113573714A CN202080020844.6A CN202080020844A CN113573714A CN 113573714 A CN113573714 A CN 113573714A CN 202080020844 A CN202080020844 A CN 202080020844A CN 113573714 A CN113573714 A CN 113573714A
Authority
CN
China
Prior art keywords
hydroxyvitamin
patient
treatment
serum
progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080020844.6A
Other languages
English (en)
Chinese (zh)
Inventor
查理斯·W·比绍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elgin Pharmaceutical Co ltd
Original Assignee
Elgin Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elgin Pharmaceutical Co ltd filed Critical Elgin Pharmaceutical Co ltd
Publication of CN113573714A publication Critical patent/CN113573714A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
CN202080020844.6A 2019-02-06 2020-02-06 用骨化二醇控制甲状旁腺功能亢进进展的方法和其中使用的组合物 Pending CN113573714A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802148P 2019-02-06 2019-02-06
US62/802,148 2019-02-06
PCT/IB2020/000089 WO2020161543A1 (en) 2019-02-06 2020-02-06 Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein

Publications (1)

Publication Number Publication Date
CN113573714A true CN113573714A (zh) 2021-10-29

Family

ID=69903711

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080020844.6A Pending CN113573714A (zh) 2019-02-06 2020-02-06 用骨化二醇控制甲状旁腺功能亢进进展的方法和其中使用的组合物

Country Status (9)

Country Link
US (1) US20220226351A1 (https=)
EP (1) EP3920938A1 (https=)
JP (2) JP2022519789A (https=)
KR (1) KR20210126023A (https=)
CN (1) CN113573714A (https=)
AU (2) AU2020218639A1 (https=)
CA (1) CA3128153A1 (https=)
MX (1) MX2020011741A (https=)
WO (1) WO2020161543A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008134523A1 (en) * 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
US20090209501A1 (en) * 2006-06-21 2009-08-20 Proventiv Therapeutics, Llc. Method of treating and preventing secondary hyperparathyroidism
AU2013203489A1 (en) * 2008-07-24 2013-05-02 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
US20130137663A1 (en) * 2010-03-29 2013-05-30 Eric J. Messner Methods and compositions for reducing parathyroid levels
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
CN108135868A (zh) * 2015-09-25 2018-06-08 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d及其制品的辅助疗法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3095447T1 (sl) * 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
DK2148684T3 (da) 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
MX2020010338A (es) * 2018-04-03 2020-11-13 Opko Ireland Global Holdings Ltd Uso de calcifediol en pacientes de cirugia bariatrica.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209501A1 (en) * 2006-06-21 2009-08-20 Proventiv Therapeutics, Llc. Method of treating and preventing secondary hyperparathyroidism
WO2008134523A1 (en) * 2007-04-25 2008-11-06 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
AU2013203489A1 (en) * 2008-07-24 2013-05-02 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
US20130137663A1 (en) * 2010-03-29 2013-05-30 Eric J. Messner Methods and compositions for reducing parathyroid levels
CN108135868A (zh) * 2015-09-25 2018-06-08 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d及其制品的辅助疗法
WO2017182237A1 (en) * 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
CN108883120A (zh) * 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SPRAGUE,SM ET AL .: "Extended‑release calcifediol for secondary hyperparathyroidism in stage 3‑4chronic kidney disease", EXPERT REV ENDOCRINOL METAB., vol. 12, no. 5, pages 289 - 301, XP055700728, DOI: 10.1080/17446651.2017.1347501 *
SPRAGUE,SM ET AL .: "Use of Extended‑Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3and 4Chronic Kidney Disease", AM J NEPHROL, vol. 44, no. 4, pages 316 - 325 *

Also Published As

Publication number Publication date
AU2025259887A1 (en) 2025-11-20
JP2025031720A (ja) 2025-03-07
KR20210126023A (ko) 2021-10-19
EP3920938A1 (en) 2021-12-15
CA3128153A1 (en) 2020-08-13
AU2020218639A1 (en) 2021-08-12
MX2020011741A (es) 2021-03-02
WO2020161543A1 (en) 2020-08-13
JP2022519789A (ja) 2022-03-24
US20220226351A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
JP2025016586A (ja) ２５－ヒドロキシビタミンｄを用いる補助的療法
US12208106B2 (en) Methods of vitamin D treatment
AU2025259887A1 (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
JP7590184B2 (ja) 肥満外科手術患者におけるカルシフェジオールの使用
HK40063649A (en) Method of controlling progression of hyperparathyroidism with calcifediol, and compositions for use therein
RU2837000C2 (ru) Применение кальцифедиола у пациентов, перенесших бариатрическую операцию
TWI918824B (zh) 維生素d治療之方法
HK40130461A (en) Methods of vitamin d treatment
HK40044272A (en) Use of calcifediol in bariatric surgery patients
BR122024014371A2 (pt) Usos de 25-hidroxivitamina d e de calcifediol para tratar hiperparatiroidismo secundário e forma de dosagem de liberação prolongada de 25-hidroxivitamina d
EA045627B1 (ru) Фармацевтическая композиция и набор для лечения или предотвращения гипокальциемии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063649

Country of ref document: HK